Real-World Data Platform Dedicated to Rare Disease Patient Participation Secures $50m

Real World Data Platform Dedicated to Rare Disease Patient Participation Secures $50m

Recently, a heavily connected San Francisco startup formally known as RDMD seeking to “unlock new treatments for people with rare disease” secured another $50 million to progress their mission to “empower patients and communities to generate regulatory-ready evidence for drug research.” Privately funded by a heavy-hitting cast of characters from Bill Gates to Mark Zuckerberg and Jeff Bezos, AllStripes’ B financing round brings the total raised to at least $67.1 million, according to Crunchbase. Lux Capital led this B round along with JAZZ Venture Partners, Spark Capital, McKesson Ventures, and others, including eClinical tech vendor Medidata Solutions (owned by Dassault Systèmes company). This most recent funding will directly support 100 rare new disease research programs while also supporting the company’s operational footprint, technology, and data automation enhancements to improve research insights, further advancing this startup’s “platform capabilities” to other use of funds, such as bolstering “life-science offerings.” TrialSite InvestorWatch reviews this venture—the vision is good, but some questions are raised.

Founded just in 2017, TrialSite provides a brie...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee